-
1.发明公开Expression of the recombinant tumor necrosis factor binding protein I (TBP-I) 失效表达重组肿瘤坏死因子 - 二氢叶酸蛋白I（TBP-1）。
公开(公告)号：EP0433900A1
公开(公告)日：1991-06-26
申请号：EP90124133.1
申请日：1990-12-13
Inventor： Wallach, David , Nophar, Yaron , Kemper, Oliver , Engelmann, Hartmut , Brakebusch, Cord , Aderka, Dan
CPC classification number: C07K14/7151 , C12N15/85 , C12N2830/002 , C12N2830/15 , C12N2830/55
Abstract: Tumor Necrosis Factor Binding Protein I (TBP-I), precursors and analogs thereof, are produced by transfecting eukaryotic cells with an expression vector comprising a DNA molecule encoding the whole human type I TNF receptor or a soluble domain thereof, and culturing the transfected cells, whereby the soluble proteins are secreted into the medium.
Abstract translation: 通过用包含编码整个人I型TNF受体的DNA分子或其可溶性结构域的表达载体转染真核细胞来产生肿瘤坏死因子结合蛋白I（TBP-1），其前体及其类似物，并培养转染的细胞 ，由此可溶性蛋白质分泌到培养基中。
-
2.发明公开Soluble extracellular fragment of the human IFN-beta 2/IL-6 receptor, its preparation and pharmaceutical compositions containing it 失效IFN-β2 / IL-6受体，其制备方法和这些含有受体的药物混合物。
公开(公告)号：EP0413908A2
公开(公告)日：1991-02-27
申请号：EP90110487.7
申请日：1990-06-01
Inventor： Novick, Daniela , Chen, Louis , Engelmann, Hartmut , Revel, Michel , Rubinstein, Menachem , Wallach, David
CPC classification number: C07K14/715 , A61K38/215 , C07K14/7155 , Y10S530/834 , A61K2300/00
Abstract: Human natural IFN-β2/IL-6 receptor and its soluble extracellular fragment are provided in substantially purified form and are shown to stimulate and to enhance beneficial effects of IFN-β2/IL-6, such as its antiproliferative activity. Polyclonal and monoclonal antibodies raised against the soluble fragment of the receptor are also provided.
Abstract translation: 人天然IFN-β2/ IL-6受体和其可溶性细胞外片段以基本上纯化的形式提供，并且被示出，以刺激和增强IFN-β2/ IL-6，颜色的有益效果：例如它的抗增殖活性。 因此，提供针对该受体的可溶性片段产生的多克隆和单克隆抗体。
-
3.发明公开A monoclonal antibody recognizing a cytotoxin, a hybridoma cell line expressing same and a process for the preparation of a purified cytotoxin 失效针对细胞毒素的单克隆抗体，用于制备纯化的细胞毒素相同的产生杂交瘤和方法。
公开(公告)号：EP0186833A2
公开(公告)日：1986-07-09
申请号：EP85115918.6
申请日：1985-12-13
Inventor： Wallach, David , Hahn, Talia , Eshhar, Zelig
CPC classification number: G01N33/56972 , A61K38/21 , C07K14/47 , C07K16/24 , G01N33/56966 , G01N2333/525 , A61K2300/00
Abstract: A cytotoxic protein expressed by human peripheral blood mononuclear cells is isolated in essentially homogenous form. This protein may be used to elicit production of polyclonal or monoclonal anti-cytotoxin antibodies. Hybridomas secreting anti-cytotoxin antibodies are identified by a solid phase bioassay. The antibodies are useful in the immunopurification of cytotoxins. The purified cytotoxic proteins are useful for the treatment of virus-infected or tumor target cells, either alone or in combination with interferon or a metabolic blocker.
Abstract translation: 通过人外周血单核细胞中过表达细胞毒性蛋白质在本质上均匀的形状是分离的。该蛋白可用于引发生产多克隆或单克隆抗细胞毒素抗体的产生。 杂交瘤分泌的抗细胞毒素抗体是通过固相生物测定识别。 抗体是在细胞毒素的免疫纯化有用。 将纯化的细胞毒性蛋白是病毒感染或肿瘤靶细胞，无论是单独使用或与干扰素或代谢阻滞剂组合的治疗是有用的。
-
4.发明授权Use of pharmaceutical compositions comprising an anticytokine for the therapy of multiple sclerosis 失效使用含有Antizytokin-药物组合物用于多发性硬化的治疗
公开(公告)号：EP0880970B1
公开(公告)日：2006-08-02
申请号：EP98104718.6
申请日：1992-05-07
Inventor： Wallach, David , Aderka, Dan , Engelmann, Hartmut
CPC classification number: A61K38/1793
-
5.发明授权Expression of the recombinant tumor necrosis factor binding protein I (TBP-I) 失效表达重组肿瘤坏死因子 - 二氢叶酸蛋白I（TBP-1）。
公开(公告)号：EP0433900B1
公开(公告)日：1995-09-20
申请号：EP90124133.1
申请日：1990-12-13
Inventor： Wallach, David , Nophar, Yaron , Kemper, Oliver , Engelmann, Hartmut , Brakebusch, Cord , Aderka, Dan
CPC classification number: C07K14/7151 , C12N15/85 , C12N2830/002 , C12N2830/15 , C12N2830/55
-
Patent Agency Ranking6.发明授权Soluble extracellular fragment of the human IFN-beta 2/IL-6 receptor, its preparation and pharmaceutical compositions containing it 失效Löslisches人类IFN金属-β2/ IL-6受体，其制备的细胞外片段和含有药物混合物该片段
公开(公告)号：EP0413908B2
公开(公告)日：2005-08-03
申请号：EP90110487.7
申请日：1990-06-01
Inventor： Novick, Daniela , Chen, Louis , Engelmann, Hartmut , Revel, Michel , Rubinstein, Menachem , Wallach, David
CPC classification number: C07K14/715 , A61K38/215 , C07K14/7155 , Y10S530/834 , A61K2300/00
-
公开(公告)号：EP0880970A1
公开(公告)日：1998-12-02
申请号：EP98104718.6
申请日：1992-05-07
Inventor： Wallach, David , Aderka, Dan , Engelmann, Hartmut
IPC: A61K38/17
CPC classification number: A61K38/1793
Abstract: Tumor Necrosis Factor Binding Proteins (TBPs) are useful in the treatment of autoimmune diseases and graft-versus-host reactions.
Abstract translation: 肿瘤坏死因子结合蛋白（TBP）是在自身免疫性疾病和移植物抗宿主反应的治疗是有用的。
-
公开(公告)号：EP0259863B1
公开(公告)日：1995-09-20
申请号：EP87113198.3
申请日：1987-09-09
Inventor： Wallach, David , Holtmann, Helmut
CPC classification number: C07K14/545 , A61K38/191 , A61K38/2006 , A61K38/21 , Y10S514/885 , A61K38/20 , A61K2300/00
-
公开(公告)号：EP0259863A3
公开(公告)日：1989-11-02
申请号：EP87113198.3
申请日：1987-09-09
Inventor： Wallach, David , Holtmann, Helmut
CPC classification number: C07K14/545 , A61K38/191 , A61K38/2006 , A61K38/21 , Y10S514/885 , A61K38/20 , A61K2300/00
Abstract: This invention relates to methods for modulating the effects of TNF and IL-1, both the deleterious and the therapeutical effect of these cytokines. In case of deleterious effects, the invention provides methods for modulating the deleterious effect of TNF and/or IL-1 in mammals, by administering to a mammal sub-deleterious amounts of TNF and/or IL-1. The TNF and/or IL-1 to be modulated may be endogenous, i.e. generated in the organism in severe cases in amounts deleterious to the organism, or exogenously administered to a patient in amounts which are potentially deleterious. The compositions of the invention comprise effective amounts of TNF and/or IL-1 with at least one pharmaceutically acceptable carrier. The invention also relates to methods for monitoring the modulation of the TNF effect in patients treated with TNF and/or IL-1.
-
10.发明公开Compositions for modulating the effect of TNF and IL-1 失效Zusammensetzungen und Methoden zur Modulation der Effekten von INF und IL-1。
公开(公告)号：EP0259863A2
公开(公告)日：1988-03-16
申请号：EP87113198.3
申请日：1987-09-09
Inventor： Wallach, David , Holtmann, Helmut
CPC classification number: C07K14/545 , A61K38/191 , A61K38/2006 , A61K38/21 , Y10S514/885 , A61K38/20 , A61K2300/00
Abstract: This invention relates to methods for modulating the effects of TNF and IL-1, both the deleterious and the therapeutical effect of these cytokines. In case of deleterious effects, the invention provides methods for modulating the deleterious effect of TNF and/or IL-1 in mammals, by administering to a mammal sub-deleterious amounts of TNF and/or IL-1. The TNF and/or IL-1 to be modulated may be endogenous, i.e. generated in the organism in severe cases in amounts deleterious to the organism, or exogenously administered to a patient in amounts which are potentially deleterious. The compositions of the invention comprise effective amounts of TNF and/or IL-1 with at least one pharmaceutically acceptable carrier. The invention also relates to methods for monitoring the modulation of the TNF effect in patients treated with TNF and/or IL-1.
Abstract translation: 本发明涉及调节这些细胞因子的有害和治疗作用的TNF和IL-1的作用的方法。 在有害作用的情况下，本发明提供了通过向哺乳动物施用有害量的TNF和/或IL-1来调节TNF和/或IL-1在哺乳动物中的有害作用的方法。 待调节的TNF和/或IL-1可以是内源性的，即在生物体中在生物体中以对生物有害的量的生物体产生，或以潜在有害的量以外源方式施用给患者。 本发明的组合物包含有效量的具有至少一种药学上可接受的载体的TNF和/或IL-1。 本发明还涉及在用TNF和/或IL-1治疗的患者中监测TNF作用的调节的方法。
-
-
-
-
-
-
-
-
-
Search Results
20
records
(took 0.029 seconds)
